



Absolute Antibody Ltd - At a glance

PRESS KIT - updated 1st June 2017

- Founded in Oxford, UK, in August 2012
- Vision to make recombinant antibody technology accessible to all
- Expanded manufacturing to the Wilton Centre in the North of England in June 2014
- 20 employees across two UK offices – recruitment active and ongoing
- Royalty-free custom antibody services – sequencing, engineering, recombinant manufacture
- Rapidly expanding recombinant reagents catalog offers over 2500 antibodies
- Annual sales volume ~ 3 million GBP
- Exports account for > 75% of sales

“All antibodies should be manufactured recombinantly - not just therapeutic antibodies”

Antibodies are outstanding tools for biomedical research, and essential components of many diagnostic tests. They are also the largest and fastest-growing source of new therapeutic drugs. The quality of the antibodies produced by pharmaceutical companies is far, far ahead of the antibodies available to everyone else.

Most antibodies used across research and diagnostics are harvested from the blood of an immunised animal, and are called ‘polyclonal antibodies’. Variation in antibody performance can occur between batches – even those harvested from the same animal. A cleaner option is to use ‘monoclonal antibodies’ which are mainly produced in cells engineered from cancer cells. These are called ‘hybridomas’ and are inherently genetically unstable, which again can result in variation of the antibody product.

At Absolute Antibody, we use a precisely defined DNA template to produce our products which enables reproducible and continuous manufacture. This is ‘recombinant’ production, and it is the only production method of a high enough quality to be used in therapeutic antibody manufacture. Our mission is to bring this level of quality to the wider research and diagnostics markets.

Since 2014, there has been a movement amongst life scientists away from unreliable antibodies that can yield misleading results which cost time and money. Founded two years before this ‘reproducibility crisis’, Absolute Antibody was ready to meet a rising demand for reliable, recombinant antibodies which are absolutely defined. We also use our expertise with recombinant technology to deliver bespoke antibody engineering projects across the whole life sciences community.

In the five years since our founding we have worked with 14 of the [top 15 pharmaceutical companies by R&D spend](#) as well as hundreds of groups from biotechnology, diagnostics, and academia. As we grow, we will continue to realise our vision: To provide recombinant engineered antibodies for all.

See also:

[Reproducibility crisis: Blame it on the antibodies](#)

[Reproducibility: Standardize antibodies used in research](#)

For press enquiries or to arrange an interview with one of our team contact PR@absoluteantibody.com.